Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other hematologic neoplasm 1NET 1Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Glioma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Specimen Handling 3Magnetic Resonance Spectroscopy 3trametinib 2dabrafenib 2Palliative Care 2Nivolumab 2Methods 2Ipilimumab 2CTLA-4 Antigen 2Biopsy 2varlilumab 1ulixertinib 1trastuzumab biosimilar HLX02 1temsirolimus 1tanespimycin 1sapanisertib 1romidepsin 1ripretinib 1relatlimab 1pertuzumab 1pembrolizumab 1peginterferon alfa-2a 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1fludarabine 1erdafitinib 1entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Lactones × Other hematologic neoplasm × Clear all
NCT01638533 2025-02-07

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
37 enrolled
BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckLymphoidNETOther hematologic neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Glioma, Lung Neoplasms, Lymphoma, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Neuroendocrine Tumors, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡